Determination of psilocin and 4HIAA in plasma and pharmacokinetic profiles of psilocybin. .
Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man
Pharm Acta Helv. 1997 23-Feb;():. 10.1016/s0031-6865(97)00014-9Twelve healthy subjects underwent controlled studies to examine the pharmacokinetic properties of psilocybin (PY). The subjects were divided equally into 2 groups where they either received oral doses or intravenous doses of PY. Quantification of the PY metabolites psilocin (PI) and 4-hydroxyindole-3-acetic acid (4HIAA) was measured through using high performance liquid chromatography with column-switching coupled with electrochemical detection (HPLC-ECD). Peak levels of PI and 4HIAA were found 105 and 113 minutes, respectively after oral PY administration. Peak PI levels were found 1.9 minutes after intravenous PY administration, while 4HIAA was not detected.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
